SAN DIEGO, Sept. 19, 2019 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) solutions, these days announced its intention to file for a Request of Continued Examination (“RCE”) of its patent application No. 15/426,617 with the US Patent Trademark Workplace (“USPTO”), titled Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction. The intent to file an RCE follows USPTO notifying the Business that the Patent Trial and Appeal Board (“PTAB”) had rejected the Company’s appeal to overturn the examiner’s choice to deny particular claims produced inside the Company’s patent application.
“While the USPTO choice is disappointing, it is significant to recognize that this is not the finish of the procedure and we strategy to request continued examination,” mentioned Joseph Dowling, Chief Executive Officer of CV Sciences. “We stay confident in guarding our intellectual home surrounding these formulations and our capability to commercialize this invention, which we think can present a remedy to a lingering epidemic in smokeless tobacco use. We will continue to concentrate on building solutions that increase the good quality of life of our clients.”
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business enterprise segments: a customer item division focused on manufacturing, promoting and promoting plant-primarily based CBD solutions to a variety of market place sectors and a drug improvement division focused on building and commercializing CBD-primarily based novel therapeutics using CBD. The Company’s PlusCBD™ Oil is the top rated-promoting brand of hemp-derived CBD on the market place, according to SPINS, the major provider of syndicated information and insights for the organic, organic and specialty solutions sector. CV Sciences’ state-of-the-art facility follows all suggestions for Excellent Manufacturing Practices (GMP) and the Company’s complete spectrum hemp extracts are processed, created, and tested all through the manufacturing procedure to confirm the cannabinoid content material meets strict business requirements. With a commitment to science, PlusCBD™ Oil was the very first hemp CBD supplement brand to invest in the scientific proof essential to acquire self-affirmed Commonly Recognized as Secure (GRAS) status.CV Sciences, Inc. has main offices and facilities in San Diego, California. Additional facts is readily available from OTCMarkets.com or by going to www.cvsciences.com.
This press release may perhaps include particular forward-hunting statements and facts, as defined inside the which means of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is topic to the Secure Harbor designed by these sections. This material includes statements about anticipated future events and/or monetary benefits that are forward-hunting in nature and topic to dangers and uncertainties. Such forward-hunting statements by definition involve dangers, uncertainties.
Speak to Info:
Investor Speak to:
Scott Van Winkle
Media Speak to: